AVITA Medical Inc (NASDAQ: RCEL, ASX: AVH) announced that its senior management team will participate in two major investor conferences in New York this September.

The company, a leading therapeutic acute wound care provider, confirmed that President and Chief Executive Officer Cary Vance and Chief Financial Officer David O’Toole will engage with investors at both events.

Conference Schedule

Management will hold investor meetings at the Lake Street Capital Markets 10th Annual Best Ideas Growth (BIG10) Conference on Thursday, September 10, 2026.

Later in the month, Vance and O’Toole will participate in a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference. The session is scheduled for Wednesday, September 16, 2026, at 1:05 pm ET.

Webcast Availability

A live audio webcast of the Morgan Stanley fireside chat will be available for replay for 90 days on the Investor Relations section of AVITA Medical’s website. The replay will be accessible starting September 17, 2026, at 3:05 am AEST.

Investors seeking one-on-one meetings or invitations for either conference are advised to contact their respective Lake Street or Morgan Stanley representatives.

AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) announced positive results from its multicenter, randomized controlled PermeaDerm-I clinical study on August 18, 2026. The data demonstrates that PermeaDerm, a biosynthetic wound matrix, provides clinically comparable outcomes to cadaveric allograft while offering a significant economic advantage for hospitals treating acute wounds.

The study met its primary endpoint, showing statistically significant superiority (p<0.001) for mean cost per percent total body surface area (%TBSA) treated. Mean treatment cost was $148.70 for every 1% TBSA treated with PermeaDerm compared with $497.10 for allograft. This represents a savings of approximately $348 per %TBSA, equating to a 70% reduction in product cost.

What the Numbers Show

The cost differential is driven by both unit pricing and operational efficiency. While the per-unit cost difference accounts for the majority of the savings, the elimination of preparation steps further enhances the economic profile. PermeaDerm reduced preparation time by 95.7% compared with allograft by eliminating tissue tracking, thawing, and meshing requirements. This operational simplification allows for off-the-shelf availability without compromising application time in the operating room.

Clinical outcomes remained comparable between treatment groups. Approximately 94% of PermeaDerm patients achieved at least 95% graft take one week following autografting, matching allograft performance. All patients in both groups achieved 95% or greater wound healing by eight weeks. No adverse events were attributed to PermeaDerm during the study.

The randomized controlled study enrolled 40 patients across 11 U.S. burn centers with wounds involving up to 30% TBSA. Following excision, patients were randomized to receive either PermeaDerm or cadaveric allograft during the temporization period before definitive split-thickness skin grafting. At final follow-up, all responding investigators and patients reported satisfaction, with responses rated as satisfied or very satisfied.

"Temporary wound coverage is a critical step between excision and definitive closure when a wound bed is not yet ready for autograft placement," said Anju Saraswat, MD, Associate Burn Director and Assistant Professor of Surgery at Atrium Health Wake Forest Baptist Burn Center and study investigator. "These results demonstrate that PermeaDerm provided clinical performance comparable to allograft with the added benefit of product transparency enabling direct visualization of the wound bed."

Cary Vance, President and Chief Executive Officer of AVITA Medical, stated that the study establishes compelling clinical and economic evidence supporting PermeaDerm as a modern alternative to allograft. He noted that combining comparable clinical performance with meaningful economic value and a simpler workflow addresses an important need for hospitals while strengthening the company’s differentiated acute wound care portfolio.

AVITA Medical will host a Key Opinion Leader webinar featuring Dr. Anju Saraswat and Dr. Christina Sharon, Burn and Acute Care Surgeon at Baton Rouge General, to review the clinical data. The event is scheduled for Tuesday, August 18, 2026, at 4:30 p.m. Eastern Time.